Lumos Pharma, Inc. (LUMO)

NASDAQ: LUMO · IEX Real-Time Price · USD
3.48
+0.02 (0.58%)
At close: Feb 3, 2023, 4:00 PM
3.49
+0.01 (0.29%)
After-hours: Feb 3, 2023, 4:00 PM EST
0.58%
Market Cap 29.15M
Revenue (ttm) 1.23M
Net Income (ttm) -28.46M
Shares Out 8.38M
EPS (ttm) -3.40
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 21,590
Open 3.44
Previous Close 3.46
Day's Range 3.42 - 3.71
52-Week Range 2.95 - 10.27
Beta 0.70
Analysts Buy
Price Target 20.91 (+500.86%)
Earnings Date Mar 8, 2023

About LUMO

Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare endocrine disorders. The company is headquartered in Austin, Texas. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2011
Employees 32
Stock Exchange NASDAQ
Ticker Symbol LUMO
Full Company Profile

Financial Performance

In 2021, Lumos Pharma's revenue was $230,000, an increase of 36.90% compared to the previous year's $168,000. Losses were -$30.43 million, 381.9% more than in 2020.

Financial Statements

Analyst Forecast

According to 12 analysts, the average rating for LUMO stock is "Buy." The 12-month stock price forecast is $20.91, which is an increase of 500.86% from the latest price.

Price Target
$20.91
(500.86% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Lumos Pharma to Participate in 12th Annual LifeSci Partners Corporate Access Event January 9-11, 2023

AUSTIN, Texas, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) th...

1 month ago - GlobeNewsWire

KOL Review of Lumos Pharma's Interim Phase 2 Data Supports Potential for New Oral Therapeutic Paradigm for Moderate Idiopathic PGHD Patients

AUSTIN, Texas, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on rare disorders, hosted two key opinion leaders (KOLs) in the fi...

1 month ago - GlobeNewsWire

Lumos Pharma to Host KOL Webinar to Discuss Interim Phase 2 Data from OraGrowtH Trials in PGHD

AUSTIN, Texas, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical stage biopharmaceutical company focused on rare endocrine disorders, announced that the Company will host ...

2 months ago - GlobeNewsWire

Lumos Pharma to Participate in the Piper Sandler 34th Annual Healthcare Conference

AUSTIN, Texas, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing a novel oral therapeutic candidate, LUM-201, through Phase 2 clinical trials fo...

2 months ago - GlobeNewsWire

Lumos Pharma (LUMO) Reports Q3 Loss, Tops Revenue Estimates

Lumos (LUMO) delivered earnings and revenue surprises of 14.85% and 24.25%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Lumos Pharma Reports Third Quarter 2022 Financial Results and Clinical Development Updates

-- Interim Data for Potentially the First Oral Medication for PGHD from Phase 2 OraGrowtH210 and PK/PD OraGrowtH212 Trials Met Expectations with an Encouraging Growth Response of 8.6 cm/yr at six mont...

2 months ago - GlobeNewsWire

Lumos Pharma Announces Encouraging Interim Results from Two Phase 2 Trials Evaluating Oral LUM-201 for Moderate Pediatric Growth Hormone Deficiency

- LUM-201, potentially the first oral medication for PGHD, met expectations in an interim analysis of two Phase 2 trials evaluating growth in Pediatric Growth Hormone Deficiency (PGHD) -

2 months ago - GlobeNewsWire

Lumos Pharma to Participate in the Cantor Neurology & Psychiatry Conference

AUSTIN, Texas, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing a novel oral therapeutic candidate, LUM-201, through Phase 2 clinical trials f...

4 months ago - GlobeNewsWire

Lumos Pharma Announces Share Repurchase Program

-- Plan to Repurchase Up to $3 Million of Common Shares -- AUSTIN, Texas, Aug. 16, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (“The Company,” NASDAQ:LUMO), a biopharmaceutical company advancing a nov...

6 months ago - GlobeNewsWire

Lumos Pharma (LUMO) Reports Q2 Loss, Tops Revenue Estimates

Lumos (LUMO) delivered earnings and revenue surprises of 4.08% and 266.36%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

Lumos Pharma Reports Second Quarter 2022 Financial Results and Clinical Development Updates

-- Continue to Anticipate Interim Data from Phase 2 OraGrowtH210 and PK/PD OraGrowtH212 Trials in Q4 2022 -- -- Primary Outcome Readouts from Both Trials Anticipated 2H 2023 with Data in up to 24 Pati...

6 months ago - GlobeNewsWire

Lumos Pharma (LUMO) Expected to Beat Earnings Estimates: Should You Buy?

Lumos (LUMO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

6 months ago - Zacks Investment Research

Lumos Pharma to Report Second Quarter 2022 Financial Results and Host Conference Call on August 9, 2022

AUSTIN, Texas, July 27, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company, today announced it will report its second quarter 2022 financial results ...

6 months ago - GlobeNewsWire

Lumos (LUMO) Soars 9.4%: Is Further Upside Left in the Stock?

Lumos (LUMO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

7 months ago - Zacks Investment Research

Lumos Pharma to Participate in Upcoming Investor Conferences

AUSTIN, Texas, May 16, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company will ...

9 months ago - GlobeNewsWire

Lumos Pharma Reports First Quarter 2022 Financial Results and Clinical Development Updates

--Phase 2 OraGrowtH210 Trial Reached 50% Randomization Milestone – Interim Data from Phase 2 and PK/PD OraGrowtH Trials Anticipated by End of 2022-- --FDA Permits Treatment with LUM-201 Beyond 12 Mont...

9 months ago - GlobeNewsWire

Lumos Pharma Announces a Clinical Collaboration with Massachusetts General Hospital (MGH) to Evaluate Oral LUM-201 in Nonalcoholic Fatty Liver Disease (NAFLD) in a Phase 2 Investigator-Initiated Trial

The IND application for this pilot trial to evaluate oral growth hormone secretagogue, LUM-201, in NAFLD has been approved by the FDA The IND application for this pilot trial to evaluate oral growth h...

9 months ago - GlobeNewsWire

Lumos Pharma to Report First Quarter 2022 Financial Results and Host Conference Call on May 10, 2022

AUSTIN, Tex., April 26, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company, today announced it will report its first quarter 2022 financial results a...

10 months ago - GlobeNewsWire

Lumos Pharma Reaches 50% Randomization Milestone in Phase 2 OraGrowtH210 Trial Evaluating Oral LUM-201 in PGHD

-   Interim Data Anticipated by End of 2022   -

10 months ago - GlobeNewsWire

Lumos Pharma to Participate in the Cantor Rare Disease Symposium

AUSTIN, Texas, March 23, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that John McKew, PhD...

11 months ago - GlobeNewsWire

Lumos Pharma Reports Full Year 2021 Financial Results and Announces Plan to Perform Interim Analyses of OraGrowtH Trials

Data from interim analyses of Phase 2 OraGrowtH210 Trial and PK/PD OraGrowtH212 Trial evaluating oral LUM-201 in PGHD anticipated by the end of 2022 Data from interim analyses of Phase 2 OraGrowtH210 ...

11 months ago - GlobeNewsWire

Lumos Pharma to Report Full Year 2021 Financial Results and Host Conference Call on March 10, 2022

AUSTIN, Texas, Feb. 23, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced it will report ...

1 year ago - GlobeNewsWire

Down 16.1% in 4 Weeks, Here's Why Lumos (LUMO) Looks Ripe for a Turnaround

Lumos (LUMO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising ear...

1 year ago - Zacks Investment Research

Wall Street Analysts Predict a 190% Upside in Lumos (LUMO): Here's What You Should Know

The mean of analysts' price targets for Lumos (LUMO) points to a 190.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts ...

1 year ago - Zacks Investment Research

Lumos Pharma Reports Third Quarter 2021 Financial Results and Provides Clinical Updates

AUSTIN, Texas, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced financial results for...

1 year ago - GlobeNewsWire